Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People with an advanced digestive cancer that has been confirmed by a tissue sample or scan, including certain types such as gastrointestinal stromal tumour (GIST), bowel cancer that has spread (mCRC), liver cancer (HCC), or certain types of pancreatic or gut neuroendocrine tumours (pNET or gepNET)
- People whose doctor is planning to treat them with one of the following standard medicines: Regorafenib, Everolimus, Sunitinib, Cabozantinib, or Encorafenib with Cetuximab — matched to their specific cancer type
- People whose doctor estimates they have a life expectancy of more than 3 months
- People whose cancer can be measured using standard medical imaging at the start of the trial
- People who are covered by a social security or equivalent health insurance system
- People who are able to give written consent before any trial procedures begin, or who have a trusted person able to confirm their consent in writing if they are physically unable to do so themselves
Who may not be able to join:
- People who are currently receiving other cancer treatments (such as chemotherapy, hormonal cancer therapy, or immunotherapy) in addition to the planned study drug
- People who still have side effects from a previous cancer treatment that are above a mild level (except hair loss or nerve tingling in the hands or feet)
- People who have previously been treated with the same specific drug that is planned for use in this trial
- People who have, or have had within the last 3 years, another active cancer — except for certain treated skin cancers or early-stage cervical cell changes that have been fully treated
- People who are pregnant, breastfeeding, or of childbearing potential and not using contraception, or people with any other condition that their doctor believes could make participation unsafe
- People who are unlikely to be able to follow the required medical appointments and check-ups due to personal, social, or geographical reasons
- People who have participated in another clinical trial using an experimental medicine within the last 30 days, or who would be doing so at the same time as this trial (with some exceptions — confirm with trial site)
- People who are under legal guardianship, protective custody, or who have had their liberty restricted
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David MALKA, Dr, Gustave ROUSSY - VILLEJUIF
Phone: +33 (0) 1 71 93 61 61
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Trough concentration (Ctrough)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.